ContraFect

28 Wells Avenue, Third Floor
Yonkers, NY 10701
United States

Tel: 914-207-2300

About ContraFect

ContraFect, a late-stage clinical biotechnology company focused on the discovery and development of biotherapeutics for life-threatening, drug-resistant infectious diseases is located in Westchester County, near New York City. We are dedicated to innovative drug development, leveraging novel technologies to create new therapies that address the high unmet medical needs of patients suffering from serious, antibiotic-resistant infections for which there are limited available treatment options. We are using ContraFect’s technical expertise to develop biotherapeutics for serious bacterial infections, including those caused by MDR and XDR strains that have high unmet medical needs, particularly products used in hospital-based markets.

It is an exciting time in our Company’s history as we advance our direct lytic agent (DLA) platform of lysins and amurin peptides into the clinic. Exebacase (CF-301), our lead lysin, is the first and only direct lytic agent to report promising results in Phase 2 and to advance to Phase 3 of development. Earlier last year, the FDA granted Breakthrough Therapy designation to exebacase for development as a treatment for MRSA bloodstream infections (bacteremia), including right-sided endocarditis, when used in addition to standard-of-care (SOC) anti-staphylococcal antibiotics. The exebacase Phase 3 study, known as the DISRUPT Study (“ Direct Lysis of Staph aureus Resistant Pathogen Trial”) ongoing in the United States and will serve as the single pivotal trial to support the BLA. ContraFect also has an active discovery pipeline of DLAs discovered at ContraFect which are progressing towards the clinic with support from major funding agencies including the Department of Defense, CARB-X and the Cystic Fibrosis Foundation. Our lead IND candidate, CF-370, a lysin targets MDR Pseudomonas aeruginosa, a bacteria identified as a serious threat in the CDC’s Antibiotic Threats in the US, 2019 report.

93 articles with ContraFect

ContraFect Announces Oral Presentations at the 30th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

1/27/2020

ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including Lysins and Amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced that it has been granted two oral presentations at the 30th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) to be held from April 18-21, 2020, in Paris, France.
ContraFect to Present at 2020 ASM Biothreats

1/22/2020

ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced that Cara Cassino, MD, Chief Medical Officer and Executive Vice President of Research has been invited to discuss the potential role of DLAs
ContraFect Partners with Leading Orthopedic Center in Europe to Provide Compassionate Use of Exebacase to Patients with Chronic Staphylococcal Prosthetic Joint Infections

1/13/2020

ContraFect Corporation announced that it has extended early access to exebacase to individual named patients with chronic post-operative prosthetic joint infections under Temporary Authorizations for Use from the French National Agency for Medicines and Health Products Safety in collaboration with Dr. Tristan Ferry at the Hôpital de la Croix Rousse in Lyon, France.
ContraFect Announces First Patient Dosed in Pivotal Phase 3 DISRUPT Study of Exebacase as a Treatment for Staph aureus Bacteremia, Including Right-Sided Endocarditis

1/10/2020

ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced the first patient has been dosed in the Phase 3 DISRUPT (Direct Lysis of Staph aureus Resistant Pathogen Trial) study of exebacase in patients with Staph aureus bacteremia,
ContraFect to Present at Biotech Showcase 2020

1/6/2020

ContraFect Corporation announced that Roger J. Pomerantz, MD, President, Chief Executive Officer, and Chairman of ContraFect will present an update on the recently initiated pivotal Phase 3 DISRUPT study of exebacase in patients with Staph aureus bacteremia, including right-sided endocarditis, and a general corporate overview at the Biotech Showcase on Monday, January 13, 2020, at 2:30 PM PT in San Francisco, CA..
ContraFect Announces Initiation of Pivotal Phase 3 DISRUPT Study of Exebacase as a treatment for Staph aureus Bacteremia, Including Right-Sided Endocarditis

12/20/2019

Superiority Trial to Confirm Significantly Improved Clinical Outcomes with Exebacase Added to Antibiotics versus Antibiotics alone to treat Methicillin-Resistant Staph aureus (MRSA) Bacteremia
ContraFect Announces First Gram-negative Product Candidate CF-370, a Direct Lytic Agent Targeting Pseudomonas aeruginosa

12/18/2019

Pre-Clinical Data Demonstrate Efficacy and Tolerability as a Potential Targeted Therapeutic for serious infections caused by multi-drug resistant P. aeruginosa
ContraFect Corporation Prices Approximately $10 Million Public Offering of Common Stock

12/17/2019

The gross proceeds from the offering will be approximately $10 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by ContraFect.
ContraFect Corporation Prices Approximately $10 Million Public Offering of Common Stock and Concurrent $3 Million Private Placement of Common Stock to Pfizer

12/10/2019

ContraFect Corporation announced the pricing of its underwritten public offering of 37,150,000 shares of its common stock at a public offering price of $0.27 per share.
ContraFect Corporation Announces Proposed Public Offering of Common Stock and Concurrent Private Placement of Common Stock to Pfizer Inc.

12/9/2019

The public offering is subject to market conditions and the private placement is contingent upon the closing of the public offering, and there can be no assurance as to whether or when the public offering and private placement may be completed, or the actual size or terms of the public offering and private placement.
ContraFect to Present at the Piper Jaffray 31st Annual Healthcare Conference

11/29/2019

ContraFect Corporation announced that Roger J. Pomerantz, MD, President, Chief Executive Officer and Chairman of ContraFect, will participate in a fireside chat at the Piper Jaffray 31st Annual Healthcare Conference on Tuesday, December 3, 2019, at 12:00 PM ET in New York City.
ContraFect Reports Third Quarter 2019 Financial Results and Provides Business Update

11/12/2019

ContraFect Corporation announced financial results for the third quarter ended September 30, 2019.
ContraFect to Present at the World Anti-Microbial Resistance Congress 2019

11/5/2019

ContraFect Corporation announced that Cara Cassino, MD, ContraFect’s Chief Medical Officer and Executive Vice President of Research & Development was invited to discuss the exebacase superiority design trial at the World Anti-Microbial Resistance Congress 2019, to be held from November 7-8, 2019, in Washington, D.C.
ContraFect to Participate in FDA Workshop on Development of Non-Traditional Therapies for Bacterial Infections

8/14/2018

ContraFect Corporation announced that Cara Cassino, M.D., the Company's Executive Vice President of Research and Development and Chief Medical Officer, has been invited by the Food and Drug Administration (FDA) to participate in a panel discussion for a public workshop entitled “Development of Non-Traditional Therapies for Bacterial Infections”.
Cell Medica Appoints Julia P. Gregory as Non-Executive Director and Audit Chair

6/13/2018

Cell Medica today announced the appointment of Julia P. Gregory as a Non-Executive Director and Audit Chair of the Company’s Board of Directors.
ContraFect Announces Third Quarter 2017 Financial Results

11/9/2017

This quarter, ContraFect completed a public stock offering raising net proceeds of $37.1 million.
ContraFect Appoints Lisa Ricciardi As Chief Operating Officer

10/5/2017
ContraFect Prices $40 Million Public Offering Of Common Stock And Warrants

7/20/2017
ContraFect Announces Proposed Public Offering Of Common Stock And Warrants

7/20/2017
ContraFect Awarded Funding From CARB-X To Support Gram-Negative Lysin Program

4/3/2017